Ph.D., BA, RT
Dr. Miller has established himself as a pioneer in gaseous nitric oxide technology and therapeutic research. In 1992, he wrote the first review paper about the potential of gaseous nitric oxide (Resp Care). In 2007, Miller characterized one of the bactericidal mechanisms of action of NO and identified the effective dose against a wide range of microbes including bacteria, fungi, parasites and viruses (Antimicrobial Agents And Chemotherapy, 2007). Miller hypothesized that the bactericidal activity of gaseous NO is retained during cyclic high dose short duration exposure (Resp Care, 2008) and validated this with in vitro technique (Nitric Oxide, 2009). He then designed and completed the first in human clinical trial demonstrating that the inhaled NO was safe in healthy adults as a potential inhaled antimicrobial strategy (Journal of Cystic Fibrosis, 2012). A major step in Miller’s research, was with the collaboration with Drs. Doering & Riethmuller (Journal Infection 2016), they completed the first human trial to study the safety and effect of inhaled NO in eight patients with cystic fibrosis. He was instrumental in the funding and design of a randomized, multi-centre, FDA study, which is ongoing with support from the American Cystic Fibrosis Foundation (NCT02498535).